Reprise Biomedical

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Reprise Biomedical sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 3 currently recruiting upper quartile by trial count

Reprise Biomedical: 3 sponsored US clinical trials, 3 recruiting.

Reprise Biomedical sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. The most-studied condition in this pipeline is Diabetic Foot Ulcers (DFUs), with 2 trials.

Upper-quartile sponsor footprint

Reprise Biomedical sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING NA

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

NCT07632001
RECRUITING NA

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686
RECRUITING NA

Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care

NCT06939673

Therapeutic Areas

Diabetic Foot Ulcers (DFUs) 2
Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer) 1
Undermined and Tunneling Wounds 1
Chronic Wounds 1
Surgical Wound Dehiscence (SWD) 1
Pressure Ulcers 1
Venous Leg Ulcers (VLUs) 1

What is open in the Reprise Biomedical pipeline

3 recruiting of 3 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Diabetic Foot Ulcers (DFUs) (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Reprise Biomedical: open-pipeline peers nationwide

Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Reprise Biomedical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Reprise Biomedical10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Reprise Biomedical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Reprise Biomedical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Reprise Biomedical page

3 registered trials is a research-attention snapshot, not an endorsement of Reprise Biomedical or any single study.

  • 3 of Reprise Biomedical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Diabetic Foot Ulcers (DFUs) is the condition Reprise Biomedical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Foot Ulcers (DFUs) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Reprise Biomedical pipeline card: 3 registered trials from official public datasets.Report a data error.